Q-omics provides the consensus-scored TEAD1 profile across patient tissues and cancer cell-line models. TEAD1 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TEAD1 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, TEAD1 RNA expression shows 20,356 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, BLCA, and ACC as cancer lineages where TEAD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TEAD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TEAD1 survival associations across molecular data types. TEAD1 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TEAD1 RNA expression–survival associations across cancer types. High TEAD1 expression shows unfavorable associations in BLCA, ACC, OV and CESC, but favorable associations in KIRC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TEAD1 RNA expression.
This table summarizes TEAD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TEAD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TEAD1 shows lower tumor expression in BLCA, KICH, BRCA and UCEC and higher tumor expression in LIHC and CHOL. The BLCA box plot shows higher TEAD1 RNA expression in normal versus tumor tissue (log2 FC = −1.107, t-test p = .003).
This table shows molecular features associated with TEAD1 in patient tissues and cancer cell lines. In patient samples, TEAD1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TEAD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and UPPER_AERODIGESTIVE_TRACT.
